Login to Your Account

TiGenix Edges up on Safety Review in Stem Cell Study

By Cormac Sheridan
Staff Writer

Wednesday, April 18, 2012
Shares in TiGenix NV gained 5 percent Tuesday on news that Cx611, its adult stem cell therapy for rheumatoid arthritis (RA), hit a key safety milestone in a Phase IIa safety trial.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription